Opinion · 22 Oct 2024
Conference abstractPublished 2021
Hydrochlorothiazide Associated Malignant Melanoma: Pharmacovigilance Signal Review
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hydrochlorothiazide (HCTZ) is a diuretic and antihypertensive. The medication has a place with a class of diuretics called thiazides diuretics. Malignant Melanoma is the most serious type of skin malignancy, creates in the cells (melanocytes) that produce melanin. The reason for this review is to assess the risk of Malignant Melanoma related to Hydrochlorothiazide use and to propose regulatory recommendations whenever required. On Aug 15, 2021, we performed a signal review utilizing World Health Organization (WHO) VigiBase, with literature screening to recover all related information to assess the causality between Malignant Melanoma and Hydrochlorothiazide use. Causality assessment was done according to the WHO-UMC system for standardized case causality assessment. The disproportionality of the observed and the expected reporting rate for the HCTZ/Malignant Melanoma pair is estimated using the information component (IC). Positive IC values reflect higher statistical association while negative values indicate less statistical association. The review resulted in 4 Individual Case Safety Reports (ICSRs). Out of four assessable ICSRs, two cases revealed probable association, and one case revealed a possible association between HCTZ use and risk of Malignant Melanoma. IC value of (-1) revealed a negative statistical association. The weighted cumulative evidence identified from cases is sufficient to validate and suggest a causal association between HCTZ and Malignant Melanoma. Therefore, health care professionals should be aware of this potential risk and may consider monitoring any signs or symptoms of Malignant Melanoma in patients treated with HCTZ.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in International Journal of Drug Development and Research.
Opinion · 22 Oct 2024
From Monoclonal Antibodies to CAR-T Therapy: Trends and Transformations in Cancer Treatment
Perspective · 21 Oct 2024
Natural Products in Drug Discovery: From Traditional Remedies to Modern Medicines
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Drug Development and Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Abdulrahman S Almutairi”
